AbbVie Skin Treatment Successful in Phase 3 Trial
July 28 2020 - 9:29AM
Dow Jones News
By Matt Grossman
AbbVie Inc. said Tuesday that its treatment for atopic
dermatitis met the main goals of a Phase 3 study.
The treatment, Rinvoq, is an orally administered JAK inhibitor
that was combined with topical corticosteroids in the study. Rinvoq
led to significantly better skin results for patients in the
16-week trial than topical corticosteroids given along with a
placebo, AbbVie said.
The results included measurements of skin clearance and itching.
Two-thirds to three-quarters of patients receiving the treatment
met a skin-clearance benchmark, compared with 11% of those who
received a placebo.
The rate of serious adverse events--in the low single-digit
range--was comparable to the level of such events in patients who
only received a placebo, AbbVie said.
Atopic dermatitis, an inflammatory condition, causes itching and
cracked, scaly skin.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
July 28, 2020 09:14 ET (13:14 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Sep 2023 to Sep 2024